Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Shares Rose 2.8% in March

By Adria Cimino – Apr 5, 2020 at 10:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Illumina shines as investors flock to shares less vulnerable to coronavirus disruptions.

What happened

Even as stocks moved into a bear market in March, shares of Illumina (ILMN 5.72%) rose 2.8% for the month, according to data provided by S&P Global Market Intelligence. Investors sought out shares of companies less vulnerable to a slowdown linked to the coronavirus outbreak.

Illumina, which develops and sells genome sequencing systems and related analysis tools, said last month that it hasn't experienced significant supply chain or other delays so far.

Illumina also announced a partnership with IDbyDNA, using the company's platform for laboratory workflow management and analysis in its next generation sequencing systems for infectious diseases. Work will start with COVID-19, the illness caused by the novel coronavirus. The genetic sequencing project may play an important role in the development of better tests to detect the virus.

A strand of DNA is shown in an image of the genetic sequencing of coronavirus.

Image source: Getty Images.

So what

Coronavirus cases now total more than 1 million worldwide, and because of the health crisis, companies in various industries have faced supply disruptions, temporary store shutdowns, and sales declines.

Medical device players have also felt the impact, with a decrease in elective surgeries that use their instruments as hospitals focus resources on the influx of COVID-19 patients. Illumina's business with laboratories and researchers insulates it to a certain degree, and its work on infectious diseases through the recent IDbyDNA partnership is a positive in this otherwise challenging time.

Now what

As for the future, Illumina's dominance in its market makes it a great long-term bet because this position supports long-term revenue and therefore share gains. According to Morningstar, Illumina holds a 70% share of the sequencing market. Illumina also has proven it can deliver results. The company surpassed analysts' estimates for earnings per share in the past four quarters, and sales and profit have gained over the past two years.

Now investors should keep their eyes on any future statements from Illumina about COVID-19. If the company doesn't report significant disruptions in the coming weeks, this should be positive for the shares in the near term as well.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina Stock Quote
$216.80 (5.72%) $11.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.